Molecular dynamics simulations reveal the role of ceramicine B as novel PPAR{\gamma} partial agonist against type 2 diabetes
원문 초록
Peroxisome proliferator-activated receptors gamma (PPAR{\gamma}) are ligand-activated controllers of various metabolic actions and insulin sensitivity. PPAR{\gamma} is thus considered as an important target to treat type 2 diabetes. Available PPAR{\gamma} drugs (full agonists) have robust insulin-sensitizing properties but are accompanied by severe side effects leading to complicated health problems. Here, we have used molecular docking and a molecular dynamics simulation study to find a novel PPAR{\gamma} ligand from a natural product. Our study suggests that the inhibition of ceramicine B in the PPAR{\gamma} ligand-binding domain (LBD) could act as a partial agonist and block cdk5-mediated phosphorylation. This result may provide an opportunity for the development of new anti-diabetic drugs by targeting PPAR{\gamma} while avoiding the side effects associated with full agonists.
함께 살펴볼 논문
공통 태그를 근거로 연결했습니다. 실제 인용 관계나 논문의 우수성을 뜻하지 않습니다.
CovDocker: Benchmarking Covalent Drug Design with Tasks, Datasets, and Solutions
PocketVina Enables Scalable and Highly Accurate Physically Valid Docking through Multi-Pocket Conditioning
PoseX: AI Defeats Physics Approaches on Protein-Ligand Cross Docking
Fast and Accurate Blind Flexible Docking
Scaling Structure Aware Virtual Screening to Billions of Molecules with SPRINT
QuickBind: A Light-Weight And Interpretable Molecular Docking Model
토론
이 논문과 연결된 포럼 글이 아직 없습니다.